Cubist Systematic Strategies, LLC Cullinan Oncology, Inc. Transaction History

Cubist Systematic Strategies, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$10.17 - $19.02 $10,556 - $19,742	-1,038 Reduced 1.82%	55,888 $952,000
Q4 2023 Feb 14, 2024	BUY	$7.89 - $10.23 $191,679 - $248,527	24,294 Added 74.45%	56,926 $580,000
Q3 2023 Nov 14, 2023	BUY	$9.05 - $11.72 $240,585 - $311,564	26,584 Added 439.55%	32,632 $295,000
Q2 2023 Aug 14, 2023	BUY	$8.8 - $13.4 $53,222 - $81,043	6,048 New	6,048 $65,000
Q3 2022 Nov 14, 2022	SELL	$11.82 - $15.42 $1.1 Million - $1.43 Million	-92,675 Reduced 86.86%	14,015 $180,000
Q3 2022 Nov 14, 2022	SELL	$11.82 - $15.42 $1.1 Million - $1.43 Million	-92,675 Reduced 86.86%	14,015 $180,000
Q2 2022 Aug 15, 2022	BUY	$7.31 - $13.55 $666,408 - $1.24 Million	91,164 Added 587.17%	106,690 $1.37 Million
Q1 2022 May 16, 2022	BUY	$10.47 - $16.75 $37,796 - $60,467	3,610 Added 30.3%	15,526 $163,000
Q4 2021 Feb 14, 2022	BUY	$15.36 - $25.0 $183,029 - $297,900	11,916 New	11,916 $184,000

146

67.6M

612K

118K

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $499M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.